[go: up one dir, main page]

TN2010000049A1 - Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same - Google Patents

Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Info

Publication number
TN2010000049A1
TN2010000049A1 TNP2010000049A TN2010000049A TN2010000049A1 TN 2010000049 A1 TN2010000049 A1 TN 2010000049A1 TN P2010000049 A TNP2010000049 A TN P2010000049A TN 2010000049 A TN2010000049 A TN 2010000049A TN 2010000049 A1 TN2010000049 A1 TN 2010000049A1
Authority
TN
Tunisia
Prior art keywords
methods
compositions
arylamino
inhibitors
mek
Prior art date
Application number
TNP2010000049A
Other languages
French (fr)
Inventor
Jean Michel Vernier
Colin Edward Rowlings
Jean Luc Girardet
Stuart Dimock
Barry Quart
Jeffrey N Miner
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of TN2010000049A1 publication Critical patent/TN2010000049A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pest Control & Pesticides (AREA)
  • Hospice & Palliative Care (AREA)
  • Dentistry (AREA)

Abstract

This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compounds and compositions described herein.
TNP2010000049A 2007-07-30 2010-01-29 Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same TN2010000049A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (1)

Publication Number Publication Date
TN2010000049A1 true TN2010000049A1 (en) 2011-09-26

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000049A TN2010000049A1 (en) 2007-07-30 2010-01-29 Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Country Status (22)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20150091434A (en)
CN (2) CN101808516B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA020624B1 (en)
EC (1) ECSP109910A (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SG189784A1 (en) * 2008-04-14 2013-05-31 Ardea Biosciences Inc Compositions and methods for preparing and using same
CA3003213C (en) * 2008-09-09 2021-07-20 F. Hoffmann-La Roche Ag Polymorphs of acyl sulfonamides
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
EA201101302A1 (en) * 2009-03-11 2012-05-30 Арди Байосайенсиз, Инк. PHARMACEUTICAL COMBINATIONS CONTAINING RDEA119 / BAY 869766 FOR THE TREATMENT OF SPECIFIC MALIGNANT NORMALIZATIONS
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
CA2777304A1 (en) * 2009-10-21 2011-04-28 Marion Hitchcock Substituted benzosulphonamides
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
EA201391587A1 (en) * 2011-04-28 2014-08-29 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч COMBINED THERAPY BASED ON HSP90
AP2013007257A0 (en) * 2011-05-27 2013-11-30 Bayer Ip Gmbh Chiral synthesis of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CA2874905A1 (en) * 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
KR20250151610A (en) 2012-06-04 2025-10-21 파마싸이클릭스 엘엘씨 Crystalline forms of a bruton's tyrosine kinase inhibitor
EP4306171A3 (en) * 2012-10-19 2024-04-03 Array Biopharma, Inc. Formulation comprising a mek inhibitor
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR102425265B1 (en) 2014-08-25 2022-07-26 에이뮨 테라퓨틱스, 인코퍼레이티드 Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
BR112019026483A2 (en) * 2017-06-16 2020-07-14 Beta Pharma, Inc. pharmaceutical formulation of n- (2- (2- (dimethylamine) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) acrylamide and its salts
KR20210142154A (en) 2019-03-21 2021-11-24 옹쎄오 DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
JP2023500906A (en) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Methods of treating cancers with acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (en) * 2024-07-02 2025-09-16 江苏海洋大学 Preparation method and application of metalloprotease 9 epitope imprinting nano-particles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
AU680635C (en) * 1992-08-25 2007-05-17 G.D. Searle Llc Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
DE69926914T2 (en) * 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
CN100441176C (en) * 2001-09-24 2008-12-10 杰西·L·S·奥 Methods and compositions for determining chemosensitizing doses of suramin for use in combination therapy
CN1681489A (en) * 2002-07-17 2005-10-12 蒂坦药物股份有限公司 Combinations of chemotherapeutic drugs that increase antitumor activity
AR040717A1 (en) * 2002-07-30 2005-04-20 Zentaris Ag USE OF ALKYLPHOSPHOCOLINES IN COMINATION WITH ANTITUMORAL MEDICINES FOR THE TREATMENT OF MALIGNAL AND BENIGAL ONCOSIS IN HUMAN AND ANIMAL BEINGS
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
EP1876167A4 (en) * 2005-04-22 2010-07-07 Kissei Pharmaceutical Crystal polymorphism of 4 -{2-ý(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino¨ethoxy}-3-isopropyl-3 ,5 -dimethylbiphenylcarboxylic acid hydrochloride
ES2481402T3 (en) * 2005-07-21 2014-07-30 Ardea Biosciences, Inc. MEK N- (arylamino) sulfonamide inhibitors
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd Novel crystals of piperacillin sodium monohydrate and process for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
CN101808516A (en) 2010-08-18
HN2010000203A (en) 2012-11-19
JP2010535232A (en) 2010-11-18
KR20150091434A (en) 2015-08-10
AP2010005134A0 (en) 2010-02-28
CN103479604B (en) 2016-08-10
PH12015501914A1 (en) 2017-07-31
NZ582929A (en) 2012-03-30
CA2693390C (en) 2017-01-17
WO2009018233A1 (en) 2009-02-05
EA032294B1 (en) 2019-05-31
JP2017125021A (en) 2017-07-20
DOP2010000045A (en) 2010-10-31
EA201000268A1 (en) 2010-08-30
CR11244A (en) 2010-05-20
MX2010001244A (en) 2010-08-31
SV2010003469A (en) 2010-04-30
CN103479604A (en) 2014-01-01
CA2693390A1 (en) 2009-02-05
HK1147396A1 (en) 2011-08-12
EA020624B1 (en) 2014-12-30
EP2184984A1 (en) 2010-05-19
MA31881B1 (en) 2010-12-01
JP6309880B2 (en) 2018-04-11
ECSP109910A (en) 2010-04-30
EA201400552A1 (en) 2014-09-30
CO6470808A2 (en) 2012-06-29
KR20100092424A (en) 2010-08-20
EP2184984A4 (en) 2013-07-24
AU2015200390B2 (en) 2017-02-23
CN101808516B (en) 2013-08-28
AU2008282338A1 (en) 2009-02-05
JP2015078199A (en) 2015-04-23
AP2817A (en) 2013-12-31
AU2008282338B2 (en) 2015-02-12
KR20140098185A (en) 2014-08-07
BRPI0815659A2 (en) 2014-09-30
IL203296A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
TN2010000049A1 (en) Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA99731C2 (en) CRYSTAL POLYMORPH FORMS OF N- (ARLYMINO) SULPHONAMIDES AS MECHANISM INHIBITORS, COMPOSITION (OPTIONS) AND APPLICATIONS
NO2023022I1 (en) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
MX2012007273A (en) Pteridinones as inhibitors of polo - like kinase.
EP3483143A8 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2012048129A3 (en) Inhibitors of polo-like kinase
IN2012DN03085A (en)
WO2010053583A3 (en) Small molecule cd4 mimetics and uses thereof
TW200613243A (en) Novel compounds
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
SA520411406B1 (en) Lysophosphatidic acid receptor 1 inhibitor compounds
MY160392A (en) Triptolide prodrugs
MY194116A (en) Pharmaceutical compounds
TW200420541A (en) Crystalline forms
MX378555B (en) Process for preparation of sulfonylurea bile acid derivatives
WO2011100502A8 (en) 7-aminofuropyridine derivatives
NO20073725L (en) CCI-779 polymorph and its use
MY159735A (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
TW200724143A (en) Novel compounds for the treatment of inflammatory diseases
UA105167C2 (en) Perindopril calcium salt or solvate thereof
NZ798990A (en) Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
TH148538A (en) N-(arylamino) sulfonamide derivatives, including polymorphisms as MEK inhibitors and their constituents, methods of application and methods for the preparation of the same.